An interpoly-stacked dielectric film with a SiO2/Si3N4/SiO2/Si (ONO) structure was prepared via the atomic-layer deposition method. The multilayer structure of the ONO film with triple interfaces was investigated via medium-energy ion scattering (MEIS). A few defects in the interface layer of the ONO structure were detected. From the X-ray photoelectron spectroscopy (XPS) results, it was presumed that the interface layer with defects in the MEIS result is due to the formation of an oxynitride layer on the unstable and rougher Si3N4 layer via. By measuring the I-V characteristics, the leakage current density and breakdown field of the ONO film were determined to be 3.4 x 10(-9) A/cm2 and 10.86 MV/cm, respectively. By estimation the C-V curve, the flat band (V(FB)) of the ONO film shifted to a negative voltage (-1.14 V), the dielectric constant (K(ONO)) of the ONO film was 5.79, and the effective interface-trapped charge density of the ONO film was about 4.96 x 10(11)/cm2.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1166/jnn.2011.4326 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A longitudinal cohort study demonstrating the beneficial effect of moderate consumption of green tea and coffee on the prevention of dementia: The JPHC Saku Mental Health Study.
J Alzheimers Dis
January 2025
Division of Cohort Research, National Cancer Center Institute for Cancer Control, National Cancer Center Japan, Tokyo, Japan.
Background: While the preventive effects of green tea and coffee on cognitive decline have been demonstrated, their long-term effects on cognition remain unclear.
Objective: This study aims to investigate the effect of green tea and coffee consumption in middle age on the prevention of dementia.
Methods: This population-based cohort study included 1155 participants (aged 44-66 in 1995).
Sex differences among sleep disordered breathing, obesity, and metabolic comorbidities; the Nagahama study.
Respir Investig
January 2025
Center for Genomic Medicine, Kyoto University Graduate School of Medicine, 53 kawahara-cho, shogoin, sakyo-ku, Kyoto, 606-8507, Japan; Department of Sleep Medicine and Respiratory Care, Division of Sleep Medicine, Nihon University of Medicine, 30-1 Ohyaguchi kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan. Electronic address:
Background: Although sex differences in the prevalence of sleep disordered breathing (SDB) is recognized, whether a sex difference exists among obese individuals with SDB with or without comorbidities has not been well investigated. This study aimed to explore the relationships of sex differences among SDB, obesity, and metabolic comorbidities.
Methods: This study evaluated 7713 community participants with nocturnal oximetry ≥2 nights.
Decreased prefrontal glutamatergic function is associated with a reduced astrocyte-related gene expression in treatment-resistant depression.
Transl Psychiatry
November 2024
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Glutamatergic dysfunction is involved in the pathophysiology of treatment-resistant depression (TRD). However, few physiological studies have evaluated its pathophysiology in vivo in individuals with TRD. Transcranial magnetic stimulation-electroencephalography (TMS-EEG) techniques can assess intracortical facilitation (ICF), which reflects glutamatergic neurophysiological function in specific cortical regions.
View Article and Find Full Text PDFSafety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.
Int J Clin Oncol
January 2025
Department of Medical Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba, 277-8577, Japan.
Article Synopsis
- Vepdegestrant (ARV-471) is an oral drug designed to degrade the estrogen receptor, specifically targeting Japanese patients with advanced ER+/HER2- breast cancer who are resistant to standard treatments.
- In a phase 1 study involving six female patients, the drug was administered at a daily dose of 200 mg, with findings showing no dose-limiting toxicities and a mean treatment duration of 9.8 weeks; most patients tolerated the treatment well, experiencing only mild adverse events.
- The pharmacokinetic data suggested similar drug absorption profiles between Japanese and Western patients, and two patients showed stable disease after 24 weeks of treatment, indicating some potential for clinical benefit.
A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer.
BJC Rep
January 2024
Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan.
Background: Nivolumab with modified FOLFIRINOX (mFOLFIRINOX) may have additive antitumour effects while minimising chemotherapy cytotoxicity. We assessed the efficacy and safety of nivolumab+mFOLFIRINOX in metastatic pancreatic cancer.
Methods: Thirty-one treatment-naïve patients aged ≥20 years with metastatic unresectable/recurrent pancreatic cancer (≥1 measurable lesion per Response Evaluation Criteria in Solid Tumours version 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!